Get the Stockscreener App
9.19
1.88%
0.17
Corvus Pharmaceuticals Inc stock is traded at $9.19, with a volume of 573.58K.
It is up +1.88% in the last 24 hours and up +62.94% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$9.02
Open:
$8.93
24h Volume:
573.58K
Relative Volume:
0.95
Market Cap:
$572.97M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-10.94
EPS:
-0.84
Net Cash Flow:
$-23.97M
1W Performance:
+3.37%
1M Performance:
+62.94%
6M Performance:
+378.65%
1Y Performance:
+570.80%
1-Day Range:
$8.87
$9.44
1-Week Range:
$7.91
$9.44
52-Week Range:
$1.23
$9.44
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by StockNews.com - MarketBeat
Corvus Pharmaceuticals stock soars to 52-week high of $8.74 By Investing.com - Investing.com Canada
Corvus Pharmaceuticals stock soars to 52-week high of $8.74 - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Hits New 12-Month HighHere's What Happened - MarketBeat
Where are the Opportunities in (CRVS) - Stock Traders Daily
Insiders Rewarded With US$3.9m Addition To Investment As Corvus Pharmaceuticals Stock Hits US$480m - Simply Wall St
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 6%Here's Why - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Rating Upgraded by Mizuho - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Lifted to "Hold" at StockNews.com - MarketBeat
Corvus Pharmaceuticals secures new South San Francisco lease - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 52-Week HighShould You Buy? - MarketBeat
Corvus Pharmaceuticals stock soars to 52-week high of $7.67 By Investing.com - Investing.com Australia
Corvus Pharmaceuticals stock soars to 52-week high of $7.67 - Investing.com India
CRVS Hits 52-week High Ahead Of Atopic Dermatitis Trial Results - RTTNews
Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment - Yahoo Finance
Upward Trajectory: Corvus Pharmaceuticals Inc (CRVS) Posts a Slidee, Closing at 6.72 - The Dwinnex
Short Interest in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Expands By 31.1% - MarketBeat
Was Corvus Pharmaceuticals Inc (CRVS)’s session last reading good? - US Post News
Corvus Pharmaceuticals Inc (CRVS) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Taking a Closer Look At Corvus Pharmaceuticals Inc (CRVS) Following Its Recent Trade - Knox Daily
Corvus Pharmaceuticals stock soars to 52-week high of $6.17 By Investing.com - Investing.com Australia
Corvus Pharmaceuticals stock soars to 52-week high of $6.17 - Investing.com India
StockNews.com Lowers Corvus Pharmaceuticals (NASDAQ:CRVS) to Sell - MarketBeat
Corvus Pharmaceuticals Inc [CRVS] insider makes an insider purchase of 20,000 shares worth 34624.0. - Knox Daily
Trading (CRVS) With Integrated Risk Controls - Stock Traders Daily
Point72 Asset Management L.P. Acquires Shares of 5,964,510 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Downgraded to "Sell" at StockNews.com - MarketBeat
When the Price of (CRVS) Talks, People Listen - Stock Traders Daily
Croda International (OTCMKTS:COIHD) Sets New 52-Week Low at $26.75 - Defense World
Cormorant Asset Management's Strategic Acquisition in Corbus Pha - GuruFocus.com
Corcept Therapeutics (NASDAQ:CORT) Sets New 52-Week High at $43.81 - Defense World
Cormorant asset management buys $7m in Corbus Pharmaceuticals stock By Investing.com - Investing.com Canada
Closing Figures Unveiled: Corvus Pharmaceuticals Inc (CRVS) Drop -7.95, Closes at 5.44 - The Dwinnex
A stock that deserves closer examination: Corvus Pharmaceuticals Inc (CRVS) - US Post News
Are Smart Investors Making the Right Decision? Corbus Pharmaceuticals Holdings Inc (CRBP) - SETE News
Top investors say Corcept Therapeutics Inc (CORT) ticks everything they need - SETE News
Samlyn Capital LLC Has $11.14 Million Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Wall Street Analyst Initiated Core Scientific Inc [CORZ]. What else is Wall St. saying - The DBT News
Where are the Opportunities in (CRBP) - Stock Traders Daily
Corcel shares drop as explorer raise funds and ups exposure in Angola - Proactive Investors USA
Corvus Pharmaceuticals Inc [CRVS] Stock bought by Insider Jones William Benton for $34624.0 - Knox Daily
Integral Health Asset Management LLC Invests $4.53 Million in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Spotlight on Corbus Pharmaceuticals: Analyzing the Surge in Options Activity - Benzinga
Evergreen Capital Management LLC Purchases 1,441 Shares of Coterra Energy Inc. (NYSE:CTRA) - Defense World
How does CRBP’s price to cash per share ratio compare in the market? - US Post News
There is no way Corsair Gaming Inc (CRSR) can keep these numbers up - SETE News
Mizuho recommends buying Corbus following its drop post-Novo's obesity data (NASDAQ:CRBP) - Seeking Alpha
450,000 Shares in Core Scientific, Inc. (NASDAQ:CORZ) Bought by P Schoenfeld Asset Management LP - MarketBeat
Core Scientific (NASDAQ:CORZ) Coverage Initiated at Canaccord Genuity Group - Defense World
Hancock Whitney Corp Has $737,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):